SCOLR controlled-delivery drugs
This article was originally published in The Tan Sheet
Executive Summary
SCOLR Pharma plans to develop 24-hour OTC pseudoephedrine decongestant and12-hour OTC combination ibuprofen/pseudoephedrine cough/cold products using the company's controlled delivery technology (CDT) platform, the firm says April 13. All three products are in the preclinical stages of development. The Bellevue, Wash.-based firm recently announced positive results from trials on 12-hour CDT pseudoephedrine and ibuprofen products and intends to submit both for FDA approval this summer (1"The Tan Sheet" April 4, 2005, p. 15)...
You may also be interested in...
Extended-Release Pseudoephedrine Trial Results “Positive,” SCOLR Says
The first of three human studies evaluating SCOLR Pharma's extended-release pseudoephedrine tablets has shown "positive" initial results, the company announced March 28
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.